SurvivorNet on MSN

Muscle invasive bladder cancer: Understanding your treatment options

Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder ...
Seeking Alpha

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
Nasdaq

Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer

Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...
Investing

Leerink Partners upgrades Relmada stock to Outperform on bladder cancer treatment potential

Investing.com - Leerink Partners upgraded Relmada Therapeutics Inc (NASDAQ:RLMD) from Market Perform to Outperform with a price target of $8.00, up from $1.00, citing potential in the company’s ...